FWM
PTCT icon

Focused Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Focused Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,200
Closed -$60K – 1155
2022
Q3 		$60K Buy
+1,200
New +$58.8K 0.01% 251
2020
Q2 		– Sell
-1,600
Closed -$71K – 806
2020
Q1 		$71K Buy
1,600
+400
+33% +$20.1K 0.02% 245
2019
Q4 		$58K Hold
1,200
– – 0.01% 302
2019
Q3 		$41K Hold
1,200
– – 0.01% 322
2019
Q2 		$54K Buy
+1,200
New +$47.4K 0.01% 315

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Focused Wealth Management's PTCT Position: Q4 2022 in Review

Focused Wealth Management sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 1,200 shares — an estimated $60K sold.

Focused Wealth Management first reported a position in PTCT in Q2 2019 and held it in 5 quarters. The position peaked at $71K in Q1 2020. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

  • Focused Wealth Management reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Focused Wealth Management sold 1,200 PTC Therapeutics shares in Q4 2022, an estimated $60K.
  • Focused Wealth Management first reported a position in PTC Therapeutics in Q2 2019 and held it in 5 quarters.
  • Focused Wealth Management's PTC Therapeutics position peaked at $71K in Q1 2020.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Focused Wealth Management's 13F filing for Q4 2022, filed 13 Jan 2023.